https://seekingalpha.com/news/4062948-earnings-preview-gilead-set-to-roll-out-q4-results-post-market-tuesday?source=feed_sector_healthcare
Feb 05, 2024 - Gilead Sciences (GILD) is expected to report a higher Q4 2023 profit on lower revenue after market close on Tuesday. Read more here.
0
sa:-3009156126378729989
0
https://www.zacks.com/stock/news/2221285/masco-mas-gears-up-to-post-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221285
Feb 05, 2024 - Inflationary pressure and demand softness are likely to get reflected in Masco's (MAS) Q4 results.
zc:781141113871865309
0
https://www.zacks.com/stock/news/2221282/omnicom-omc-to-post-q4-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_article-2221282
Feb 05, 2024 - Omnicom's (OMC) fourth-quarter 2023 earnings and revenues are likely to increase year over year.
zc:-5520237136010062035
0
https://www.zacks.com/stock/news/2221283/paypal-pypl-to-post-q4-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221283
Feb 05, 2024 - PayPal's (PYPL) fourth-quarter results are expected to reflect strength across Venmo, Checkout experiences and BNPL solutions amid macro headwinds.
zc:-6024672259441460380
0
https://www.zacks.com/stock/news/2221272/under-armour-uaa-to-post-q3-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221272
Feb 05, 2024 - Under Armour's (UAA) third-quarter fiscal 2024 results are expected to reflect challenges in the North America market. However, its focus on growth strategies is likely to have aided.
zc:-8788145687630850940
0
https://www.zacks.com/stock/news/2221240/wynn-resorts-wynn-to-post-q4-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221240
Feb 05, 2024 - Wynn Resorts' (WYNN) fourth-quarter 2023 performance is likely to have benefited from its Macau operations, sports-betting expansion and non-gaming revenue boosting strategies.
zc:2673393193681822181
0
https://www.zacks.com/stock/news/2221181/bio-rad-laboratories-bio-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221181
Feb 05, 2024 - Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
zc:-3836222881949672549
0
https://www.zacks.com/stock/news/2221182/mattel-mat-to-post-q4-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221182
Feb 05, 2024 - Mattel's (MAT) fourth-quarter performance is likely to have benefited from a robust product line-up, IP-driven strategy and cost-control efforts.
zc:1381673643409617182
0
https://www.zacks.com/stock/news/2221180/encompass-health-ehc-to-post-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2221180
Feb 05, 2024 - Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.
zc:4466983977955815392
0
https://seekingalpha.com/article/4667245-us-weekly-fundflows-insight-report-shortintermediate-government-and-treasury-etfs-post-largest-outflow-on-record?source=feed_tag_etf_portfolio_strategy
Feb 02, 2024 - At the close of LSEG Lipper’s fund-flows week, U.S. broad-based equity indices reported mixed to negative returns.
0
sa:-7910337874979433039
0